Intervention Review

You have free access to this content

Somatostatin analogues for pancreatic surgery

  1. Kurinchi Selvan Gurusamy*,
  2. Rahul Koti,
  3. Giuseppe Fusai,
  4. Brian R Davidson

Editorial Group: Cochrane Upper GI and Pancreatic Diseases Group

Published Online: 30 APR 2013

Assessed as up-to-date: 14 FEB 2013

DOI: 10.1002/14651858.CD008370.pub3


How to Cite

Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008370. DOI: 10.1002/14651858.CD008370.pub3.

Author Information

  1. Royal Free Campus, UCL Medical School, Department of Surgery, London, UK

*Kurinchi Selvan Gurusamy, Department of Surgery, Royal Free Campus, UCL Medical School, Royal Free Hospital,, Rowland Hill Street, London, NW3 2PF, UK. kurinchi2k@hotmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 3]
Figure 3. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 Somatostatin analogues versus none, outcome: 1.1 Perioperative mortality.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Somatostatin analogues versus none, Outcome 1 Perioperative mortality.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Somatostatin analogues versus none, Outcome 2 Treatment withdrawal.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Somatostatin analogues versus none, Outcome 3 Number with adverse effects due to treatment.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Somatostatin analogues versus none, Outcome 4 Re-operation.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Somatostatin analogues versus none, Outcome 5 Anastomotic leak.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Somatostatin analogues versus none, Outcome 6 Pancreatic fistula (all).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Somatostatin analogues versus none, Outcome 7 Pancreatic fistula (clinically significant).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Somatostatin analogues versus none, Outcome 8 Postoperative pancreatitis.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Somatostatin analogues versus none, Outcome 9 Sepsis.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Somatostatin analogues versus none, Outcome 10 Renal failure.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Somatostatin analogues versus none, Outcome 11 Bleeding.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Somatostatin analogues versus none, Outcome 12 Abdominal collections.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Somatostatin analogues versus none, Outcome 13 Infected abdominal collections.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Somatostatin analogues versus none, Outcome 14 Delayed gastric emptying.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Somatostatin analogues versus none, Outcome 15 Pulmonary complications.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Somatostatin analogues versus none, Outcome 16 Shock.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Somatostatin analogues versus none, Outcome 17 Number of complications.
[Analysis 1.18]
Analysis 1.18. Comparison 1 Somatostatin analogues versus none, Outcome 18 Number with any complication.
[Analysis 1.19]
Analysis 1.19. Comparison 1 Somatostatin analogues versus none, Outcome 19 Hospital stay.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Somatostatin analogues versus none (stratified by different interventions), Outcome 1 Perioperative mortality.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Somatostatin analogues versus none (stratified by different interventions), Outcome 2 Treatment withdrawal.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Somatostatin analogues versus none (stratified by different interventions), Outcome 3 Number with adverse effects due to treatment.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Somatostatin analogues versus none (stratified by different aetiologies), Outcome 1 Perioperative mortality.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Somatostatin analogues versus none (stratified by different aetiologies), Outcome 2 Treatment withdrawal.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Somatostatin analogues versus none (stratified by different aetiologies), Outcome 3 Number with adverse effects due to treatment.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Somatostatin analogues versus none (pancreatoduodenectomy), Outcome 1 Perioperative mortality.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Somatostatin analogues versus none (pancreatoduodenectomy), Outcome 2 Treatment withdrawal.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Somatostatin analogues versus none (pancreatoduodenectomy), Outcome 3 Number with adverse effects due to treatment.